Legacy today announced a revamp of its clinical offering, expanding access to semen analysis for patients and providers.
The company is launching its Basic Semen Analysis. Priced at $145, the product uses Legacy's mail-in process, time-to-analysis and motility preservation to provide reliable results for patients.
The launch builds on recent lower-cost offerings, including post-vasectomy semen analysis (PVSA) and Legacy's proprietary Sperm Insights product.
These changes reflect Legacy's broader strategy to increase accessibility to male fertility testing — particularly for individuals paying out-of-pocket — and to deliver a more comprehensive, flexible solution for clinics across the United States.
The Basic Semen Analysis maintains Legacy's standards and includes key clinical parameters:
- Volume
- Count
- Concentration
- Motility, including estimated initial motility
- Progressive motility
The Basic Semen Analysis excludes morphology, allowing for a streamlined, cost-effective option while preserving critical diagnostic value.
In another move that improves affordability of male fertility care, Legacy clinician partners and patients can now access Advanced Semen Analysis, which includes DNA fragmentation testing, for $495.
This adjustment reflects growing clinical demand for DNA fragmentation analysis, particularly among reproductive endocrinologists and urologists. Legacy is the highest volume provider of DNA fragmentation testing nationwide.
Additionally, starting this month, patients that have previously completed a standard semen analysis will be able to order a stand-alone DNA fragmentation test at a lower price point.
